Diagnostic Center | October 09, 2022
ICON selected by BARDA to conduct anthrax vaccine clinical trial
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
Construction will begin this year with the new capacity anticipated by 2025
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
This agreement is in addition to the $92 million filling line expansion announced in November 2021
New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)